Omnigen®: An effective and unique ocular surface regenerative therapy solution (#2849)

Creation
Draft
Initial
Detailed
Accepted
Adoption
Idea Description
Supplementary Information
Innovation 'Elevator Pitch':
Omnigen® is a unique ‘off-the-shelf’ transportable biological matrix that can be used as an effective surgical and in clinic regeneration therapy for a range of wound care and ocular surface disorders.
Overview of Innovation:
The ocular surface comprises the cornea, conjunctiva, eyelids and lacrimal glands, and any disorder in these structures can be classified as an ocular surface disorder (OSD). Though the prevalence of OSD is quite high, unfortunately, cases often go undiagnosed or undertreated, due to a lack of understanding of symptoms and inaccurate evaluation. As people are living longer, these disorders are becoming more prevalent, but awareness about them is limited.

Omnigen is an innovative sight saving and wound care regenerative therapy that retains the natural regenerative properties of fresh amniotic membrane (amnion) in a dry and stable transplant matrix. Omnigen equips civilian and military clinicians with an easy accessible and easy to use regenerative therapy, allowing them to effectively treat OSD and trauma in surgery, in the clinic or in the emergency room.

Omnigen is supplied in a bespoke delivery tray. It is easy to manipulate and applied dry, directly to the eye, where it can be rapidly rehydrated by ambient in vivo moisture of the eye. The epithelial side is marked for confident orientation.

Omnigen contains no viable cells. It is stored and shipped at room temperature (25˚C) and is ready to use straight from the sterile pack. There is no longer any need to be concerned with keeping amnion frozen, thawing it, having to pre-plan use or risk wastage.

Omnigen retains the originality of amnion. It is manufactured using a patented preparation and drying process (Tereo®). This process allows retention of the natural trophic components present in fresh amnion; an element believed to be linked to wound healing performance (Allen C.L., et al 2013).

Omnigen is a stable matrix developed so that it may be stored at the point-of-care. As a stock product, it is therefore ready to use immediately when clinically required. Omnigen can thus be routinely accessed in emergency situations to treat the diseased ocular surface.



Omnigen is processed from amnion donated by UK donors undergoing elective caesarean section births at NHS hospitals. Donor eligibility is assessed via the donor’s history, a face-to-face medical/social history interview and mandatory blood tests. Omnigen is aseptically processed under Grade A clean room conditions and undergoes antibiotic decontamination. The culture negative microbiological status of the processed product is validated by an independent laboratory prior to release.


Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
Similar Content2
Innovation 'Elevator Pitch':
Revamil Gel 100% Pure Honey:
  • Sizes: 18g tube
  • 100% pure Revamil honey
  • Not contra-indicated for diabetic patients
  • Low 3.5 PH balance
  • Can be used for 3 months after opening (same patient)
  • Suitable for all age groups
  • No pesticides or parabens

 
Overview of Innovation:
Revamil hydrophilic wound gel (18g) consists of 100% pure, medicinal honey with a high enzyme content and a low ph. The carefully controlled production process guarantees that Revamil wound gel does not contain any traces of pesticides or parabens and that the same quality can be reproduced consistently.

Revamil gel supports wound healing through antibacterial protection and is particularly suitable for chronic and infected wounds.
  • Revamil wound gel creates a moist wound environment which stimulates healing.
  • Revamil wound gel neutralises wound odours.
  • Revamil wound gel creates a protective layer over the wound.
  • Revamil wound gel can be used on the following wound types:Chronic wounds, infected wounds, acute wounds, deep wounds, surgical oncological wounds, radiation induced oncological wounds, 1st and 2nd degree burns.
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
In the clinical testing carried out Revamil honey killed Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa within 2 hours, whereas manuka honey, the comparator dressing, widely used within the NHS and had such rapid activity, only against B. subtilis. After 24 hours of incubation, both honeys killed all tested bacteria, including methicillin-resistant Staphylococcus aureus.
 
This would greatly improve wound healing outcomes and allow the patient to move along the wound healing pathway quicker as Revamil honey kills bioburden more rapidly within the wound site. The outcome meaning less dressing changes, reduced nursing time and greater patient comfort and efficacy.

Revamil honey dressing are 100% pure honey dressing and costings verses other 100% pure honey dressings and non-honey dressing Revamil is priced very favourably and can offer both CCG and Trust monitory savings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Case studies have been performed by Professor Steve Jeffrey, Burns and Plastics, Q.E Hospital, Birmingham, using Revamil gel in the treatment of several burns on a varied patient group.
 
This article was published in the BJN (March 2019) and demonstrated the success of using Revamil gel dressings on a variety of burns patients within a hospital setting. The impact of such success can lead to patient’s wellbeing and health benefiting from quicker hospital discharge times as well as accelerated wound healing, reduced scaring and long-term psychological effects that stagnant painful wounds have on patients. Revamil gel dressing use can therefore support local health boards in cost efficiency and allow, where appropriate, an earlier return to work for the patient.
Current and planned activity: 
Currently underway:
  • Manchester Children’s Hospital – Trial of 50 patients (Burns)
  • Royal Preston Hospital – Trial burns unit (adults)
  • Stafford community – Trial tissue viability
  • Plymouth community – Trial tissue viability
  • Kent community – Trial tissue viability
We are seeking West Midlands partners to assist with clinical evaluation to create a UK evidence base, taking a holistic view of the economic impact from a department (Trust) and patient perspective.
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
Innovation 'Elevator Pitch':
Revamil Balm:
  • Size: 15g tube
  • 25% pure Revamil honey per tube
  • Not contra-indicated for diabetic patients
  • Low 3.5 PH balance
  • Can be used for 3 months after opening (same patient)
  • Suitable for all age groups
  • No pesticides or parabens
Overview of Innovation:
Revamil Balm is a combination of a skin-protecting, neutral ointment combined with enzyme rich medical grade pure honey. The ointment has both effective wound-healing and antibacterial properties due to its high honey content. Revamil Balm is kind to the skin and is primarily suitable for the treatment of surface wounds, such as grazes and dermatological conditions such as eczema.
  • Revamil Honey creates a moist wound environment which stimulates healing
  • Revamil neutralises wound odours, wound odour may occur due to bacteria within the wound environment
  • Revamil balm does not leave a sticky residue
Revamil Balm can be used on the following wound types:
  • Superficial wounds and dermatological conditions
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Innovation and adoption / Person centred care
Benefit to NHS:
In the clinical testing carried out Revamil honey killed Bacillus subtilis, Escherichia coli and Pseudomonas aeruginosa within 2 hours, whereas manuka honey, the comparator dressing, widely used within the NHS and had such rapid activity, only against B. subtilis. After 24 hours of incubation, both honeys killed all tested bacteria, including methicillin-resistant Staphylococcus aureus.
 
This would greatly improve wound healing outcomes and allow the patient to move along the wound healing pathway quicker as Revamil honey kills bioburden more rapidly within the wound site. The outcome meaning less dressing changes, reduced nursing time and greater patient comfort and efficacy.

Revamil honey balm dressing have 25% pure honey in each tube and is suitable for patients with sensitive wounds or unable to tolerate a secondary dressing. The scope in which Revamil balm can be applied allows HCP to treat wounds that would be often problematic for the patient and could lead to patient non-compliancy. Revamil balm can support HCP in treating patients and speeding up the wound healing process. This in turn will help to reduce cost and medicinal wastage on local CCGs and Trusts and allow the patient, when applicable get back to work quicker.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Case studies have been performed by Professor Steve Jeffrey, Burns and Plastics, Q.E Hospital, Birmingham, using Revamil gel in the treatment of several burns on a varied patient group.
 
These case studies have demonstrated the success of using Revamil balm dressings on a variety of burns patients within a hospital setting. The impact of such success can lead to patient’s wellbeing and health benefiting from quicker hospital discharge times as well as accelerated wound healing, reduced scaring and long-term psychological effects that stagnant painful wounds have on patients. Revamil balm dressing use can therefore support local health boards in cost efficiency and allow, where appropriate, an earlier return to work for the patient.
Current and planned activity: 
Currently underway:
  • Manchester Children’s Hospital – Trial of 50 patients (Burns)
  • Royal Preston Hospital – Trial burns unit (adults)
  • Stafford community – Trial tissue viability
  • Plymouth community – Trial tissue viability
  • Kent community – Trial tissue viability
We are looking for West Midlands partners to assist with a clinical evaluation to create UK outcome data taking a holistic view of the economic impact from a department (Trust) and patient perspecitive.

 
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
2 years
Ease of scalability: 
2
Read more
Hide details
0
0
Votes
-99999

Created by

Share and Follow